Twenty (19%) patients were on immunosuppressive agents at least once (lasting at least 6 months) during follow-up, including one of the available DMTs in China (beta-interferon or teriflunomide), or off-label drugs (azathioprine, mycophenolate mofetil, or rituximab); two (1.9%) patients had initiated treatment prior to their second-attack (both on teriflunomide) and 1 (1.0%) (teriflunomide) prior to diagnosis of McDonald MS. The gene discussed is IFNB1; the disease is myeloid sarcoma.